Wilms tumor protein 1-derived peptides presented on Major Histocompatibility Complex class I and II (WT1-MHC)

Wilms tumor protein 1 (WT1) is a zinc-finger transcription factor that plays a pivotal role in cell growth, differentiation, and apoptosis (Source: UniProt P19544). While its expression is largely restricted to specific tissues like the kidneys and hematopoietic stem cells in adults, it is significantly overexpressed in a wide array of hematological malignancies and solid tumors (Source: National Cancer Institute). WT1-derived peptides are processed by the proteasome and presented on the cell surface by Major Histocompatibility Complex (MHC) class I and II molecules, making them accessible to T-cell receptors (TCRs) (Source: Nature Reviews Cancer). These peptide-MHC complexes are the primary targets for various immunotherapeutic approaches, including peptide vaccines like Galinpepimut-S and TCR-engineered T-cell therapies (Source: SELLAS Life Sciences, PubMed PMID: 28811011). By targeting these specific epitopes, clinicians aim to induce a robust cytotoxic T-lymphocyte response against tumor cells while minimizing damage to healthy tissues. The success of these therapies often depends on the patient's HLA genotype and the density of WT1 peptide presentation on the tumor surface.

Other names

WT1-HLA complexWT1 peptide-MHCWilms tumor 1 antigenWT1-pMHCWT1-derived epitopes

Induction of T-cell mediated cytotoxicity and helper T-cell activation through the recognition of WT1-derived peptides presented by MHC class I and II molecules on the surface of tumor cells.